DANIEL GRASSO: Open Payments
NPI 1649900234 · GRAND BLANC, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$8,751 in 180 payments from 16 companies in 2025. Trend: 2023 $1,459 · 2024 $1,813 · 2025 $8,751
Speaker / faculty: $5,212Food & beverage: $3,125Travel & lodging: $213Education: $201
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 32 | $5,904 |
| Teva Pharmaceuticals USA, Inc. | 19 | $444 |
| Axsome Therapeutics, Inc. | 20 | $434 |
| E.R. Squibb & Sons, L.L.C. | 19 | $285 |
| Alkermes, Inc. | 11 | $267 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $267 |
| Supernus Pharmaceuticals, Inc. | 16 | $219 |
| Lundbeck LLC | 11 | $197 |
| Vanda Pharmaceuticals Inc. | 11 | $188 |
| Collegium Pharmaceutical, Inc. | 3 | $155 |
Products named: REXULTI, Auvelity, COBENFY, CAPLYTA, Qelbree, FANAPT, AUSTEDO XR, ARISTADA.
Industry payments across MI — which companies pay providers there.
